CSF1R and neoplasm: showed that a CSF1R inhibitor (PLX3397) combined with oncolytic adenoviruses and anti-PD-1 significantly promoted tumor regression and extended survival, as compared to single or dual therapies, in colon cancer models by depleting TAMs (Shi et al., 2019).